ONCAlert | Upfront Therapy for mRCC

Ovarian Cancer VIEW MORE >>

Preliminary data showed that the combination of sitravatinib and tislelizumab is well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which reported data from a phase Ib study at the 2019 European Society of Oncology Immuno-Oncology Congress in Geneva, Switzerland.
 

Latest JournalAll Journals >>

Targeted Therapies in Oncology November 2 2019
Targeted Therapies in Oncology
MORE >>
The Targeted Oncology ovarian cancer resource center provides the latest clinical updates about the disease state, with a plethora of ovarian cancer news articles covering the most up-to-date advancements in the field, as well as exclusive interviews with key ovarian cancer opinion leaders. Visitors to the site will find news that highlights both current and emerging ovarian cancer treatment options, as well as updates from the world’s most attended oncology conferences and annual meetings, including key coverage almost immediately after it is presented.

Additionally, video interviews and case studies from gynecologic oncologists and professionals specializing in ovarian cancer can be found on this page, offering expert guidance on the presentation of early ovarian cancer symptoms, tips and advice for management of the disease, and treatment options for patients. The web version of The Journal of Targeted Therapies, also found here, offers the most up-to-date data from recently completed clinical trials, analyses, and ongoing studies in patients in all stages of ovarian cancer.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.